Type 2 Diabetes: Finding the Right Clinical Trial

Why Clinical Trials Matter for Type 2 Diabetes Management

Clinical trials are not a last resort. For Type 2 Diabetes, they represent access to drug classes that may reduce HbA1c, body weight, and cardiovascular risk simultaneously, sometimes years before FDA approval. The ADA 2024 Standards of Care state that "participation in clinical research is an opportunity that should be discussed with all people with diabetes." [1]

The Gap Between Guidelines and Available Drugs

Standard-of-care algorithms already include metformin, GLP-1 receptor agonists, and SGLT2 inhibitors. Yet roughly 50% of U.S. Adults with Type 2 Diabetes still have HbA1c above 7.0% despite treatment, according to CDC National Diabetes Statistics Report data. [2] Trials test next-generation agents that target residual glycemic burden and the cardiometabolic complications that current drugs do not fully address.

Who Benefits Most From Trial Participation

Adults with HbA1c between 7.5% and 10.5%, at least one cardiovascular risk factor, and a body mass index above 27 kg/m² are the most commonly recruited phenotype in Phase 3 trials. That description matches approximately 38 million Americans currently living with Type 2 Diabetes. [2] Patients with early-stage disease (HbA1c 6.5%, 7.4%) qualify for prevention and durability trials. Patients with advanced nephropathy or recent acute coronary syndrome qualify for targeted outcomes studies.

Understanding Your Current Treatment Stage Before You Search

Before searching ClinicalTrials.gov, map your own treatment history. Trials stratify by background therapy, and applying to the wrong stratum wastes weeks.

Background Therapy Categories Used in Most Protocols

Most Phase 3 protocols define three strata:

• Metformin-only: HbA1c 7.0%, 10.0%, on stable metformin ≥1,500 mg/day for ≥12 weeks.
• Metformin plus one additional agent: Typically an SGLT2 inhibitor or sulfonylurea added for ≥8 weeks.
• Insulin-based regimens: Basal insulin at ≥20 units/day, sometimes combined with a GLP-1 RA.

The DECLARE-TIMI 58 trial (N=17,160) enrolled patients on any background glucose-lowering therapy except another SGLT2 inhibitor, which is a typical inclusion approach for SGLT2 outcome studies. [3] Knowing your exact regimen before you call a trial site speeds up the pre-screening call from 45 minutes to under 15.

Renal Function: The Most Common Deal-Breaker

EGFR below 30 mL/min/1.73m² excludes participants from most glucose-lowering trials. SGLT2 inhibitor trials specifically require eGFR ≥20 or ≥45 depending on the primary endpoint. The CREDENCE trial (N=4,401) set an eGFR entry floor of 30, which led to approximately 12% of initially screened patients being excluded for renal criteria alone. [4] Get a current metabolic panel before you apply.

The Major Drug Classes Being Studied Right Now

GLP-1 Receptor Agonists

Semaglutide (Ozempic/Wegovy) and liraglutide (Victoza) are already approved, but trials are testing higher doses, oral formulations, and combination agents. SUSTAIN-6 (N=3,297) showed subcutaneous semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events (MACE) by 26% vs. Placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority). [5] Current trials test oral semaglutide at 25 mg and 50 mg daily for additional HbA1c reduction.

Dual GIP/GLP-1 Agonists

Tirzepatide (Mounjaro) changed the benchmarks. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly. The 15 mg tirzepatide arm produced a mean HbA1c reduction of 2.46% vs. 1.86% for semaglutide (P<0.001). [6] The SURMOUNT-2 trial (N=938), focused on adults with Type 2 Diabetes and obesity, showed 15.7% mean body weight reduction at 72 weeks on tirzepatide 15 mg vs. 3.3% on placebo. [7] Next-generation dual and triple agonists (GLP-1/GIP/glucagon) are now in Phase 2.

SGLT2 Inhibitors

Empagliflozin, dapagliflozin, and canagliflozin have mature cardiovascular outcome data. EMPA-REG OUTCOME (N=7,020) showed empagliflozin reduced the risk of CV death by 38% (HR 0.62; 95% CI 0.49 to 0.78; P<0.001) in patients with established cardiovascular disease. [8] Active trials now test SGLT2 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) who also carry a Type 2 Diabetes diagnosis, a cohort historically underrepresented in earlier outcome trials.

Novel Insulin Formulations and Insulin Sensitizers

Ultra-long-acting insulins and once-weekly basal insulins are in late-stage trials. Insulin icodec (once-weekly basal) was tested in the ONWARDS 1 trial (N=582), where it achieved non-inferior HbA1c reduction vs. Once-daily insulin glargine U100, with a similar rate of clinically significant hypoglycemia. [9] Trials for insulin-naive patients with Type 2 Diabetes remain some of the most accessible for newly diagnosed individuals who have not yet started injectable therapy.

How to Find and Evaluate a Trial: A Step-by-Step Approach

Finding a trial takes a structured process, not a single search. Use the four-stage framework below.

Stage 1: Define Your Inclusion Profile in Five Data Points

Before opening any database, write down:

1. Current HbA1c (must be within 90 days).
2. Current medications and doses (confirm stability duration).
3. Most recent eGFR and urine albumin-to-creatinine ratio (UACR).
4. Any cardiovascular history (MI, stroke, heart failure, peripheral arterial disease).
5. BMI and current weight in kilograms.

These five data points map to the five most common axis of stratification across Type 2 Diabetes Phase 2 and Phase 3 protocols.

Stage 2: Search ClinicalTrials.gov With Precision Filters

Go to clinicaltrials.gov and use these filter combinations:

• Condition: Type 2 Diabetes
• Status: Recruiting
• Phase: Phase 2 or Phase 3 (Phase 1 trials rarely enroll patients with active comorbidities)
• Age: Your age
• Location: Within 50 to 100 miles of your zip code

As of July 2025, this filter set returns approximately 340 actively recruiting Phase 2/3 studies in the United States. The ADA 2024 Standards of Care explicitly recommend clinicaltrials.gov as the primary discovery resource for patients and clinicians. [1]

Stage 3: Read the Eligibility Criteria Before Calling

Every trial listing includes an "Eligibility" tab. Focus on these three items first: HbA1c range required, eGFR floor, and list of prohibited concomitant medications. If your current HbA1c sits below the trial's minimum (commonly 7.5%), you will fail screening. The FDA's Guidance for Industry on diabetes drug development explicitly requires sponsors to define and enforce these glycemic entry criteria to ensure interpretable results. [10]

Stage 4: Pre-Screen by Phone, Then Confirm In-Person

Call the site coordinator. Most sites conduct a 10-to-15-minute pre-screening call that covers the five data points from Stage 1. If you pass pre-screening, the site schedules a full screening visit that includes confirmatory labs, ECG (for QT-prolonging agents), and a review of your medication history. Expect the in-person screening visit to take two to three hours.

Cardiovascular Outcome Trials: A Special Category

Cardiovascular outcome trials (CVOTs) are the largest and most impactful category in Type 2 Diabetes research. The FDA's 2008 guidance required all new diabetes drugs to demonstrate cardiovascular safety, a mandate that produced landmark trials like LEADER (liraglutide), EMPA-REG OUTCOME (empagliflozin), and DECLARE-TIMI 58 (dapagliflozin). [10]

Who Qualifies for a CVOT

CVOTs typically require either:

• Established cardiovascular disease: Prior MI, stroke, unstable angina requiring hospitalization, coronary revascularization, or symptomatic peripheral arterial disease.
• High cardiovascular risk: Age ≥55 with at least two of the following: hypertension on medication, dyslipidemia on medication, current smoking, microalbuminuria or macroalbuminuria, or LVH on ECG.

The LEADER trial (N=9,340) enrolled patients in both categories and showed liraglutide reduced MACE by 13% vs. Placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). [11] Many active CVOTs enroll the same dual-category population.

Monitoring Intensity in CVOTs

CVOTs require more frequent study visits than standard glucose-lowering trials. Typical visit schedules include: in-person visits every three months for the first year, then every six months, with phone contact at alternating intervals. Labs drawn at most visits include HbA1c, lipid panel, renal panel, and urine UACR. For patients who want close medical monitoring as part of trial participation, a CVOT often provides more clinical oversight than routine primary care.

Renal and Cardiorenal Trials

SGLT2 inhibitor trials targeting diabetic kidney disease have become a distinct sub-category since the CREDENCE and DAPA-CKD results. CREDENCE (N=4,401) demonstrated canagliflozin reduced the composite renal endpoint (ESKD, doubling of serum creatinine, renal or CV death) by 30% vs. Placebo (HR 0.70; 95% CI 0.59 to 0.82; P<0.001). [4]

Nephrology-Based Enrollment Criteria

Active cardiorenal trials typically require:

• Type 2 Diabetes diagnosis confirmed by two measurements.
• eGFR 20 to 75 mL/min/1.73m² (specific floor and ceiling vary by protocol).
• UACR ≥200 mg/g to confirm albuminuric phenotype.
• Stable ACE inhibitor or ARB therapy for ≥4 weeks.

Patients with eGFR in the 20 to 45 range who were previously excluded from glucose-lowering trials now have specific trials designed around their phenotype. This represents a meaningful change from the enrollment patterns of trials conducted before 2015.

Weight-Focused Trials in Type 2 Diabetes

Weight reduction is now a co-primary endpoint in many Type 2 Diabetes trials, reflecting the metabolic overlap between obesity and insulin resistance. The SURPASS-CVOT trial (N=14,000+) testing tirzepatide against dulaglutide is still ongoing, but interim data and the completed SURMOUNT-2 data set a high bar for expected weight reduction in the T2D population. [7]

BMI Thresholds and Weight-Loss Trial Eligibility

Most weight-focused trials require BMI ≥27 kg/m² with at least one weight-related comorbidity, or BMI ≥30 kg/m² without additional criteria. Trials testing agents with a primary obesity indication (semaglutide 2.4 mg, tirzepatide 10/15 mg) that also include a T2D sub-cohort may require HbA1c below 10.0% to ensure participants are not in urgent need of intensified glucose-lowering therapy outside the trial.

In STEP-2 (N=1,210), which focused specifically on adults with Type 2 Diabetes and obesity, semaglutide 2.4 mg produced 9.6% mean body weight reduction vs. 3.4% placebo at 68 weeks (P<0.001). [12] That 6.2 percentage-point difference translated to approximately 6.3 kg absolute weight loss advantage.

Practical Eligibility Checklist Before Your First Call

Use the table below to rapidly triage whether a specific trial is worth a pre-screening call.

| Eligibility Axis | Typical Requirement | Your Data | |---|---|---| | HbA1c | 7.0%, 10.5% | ___% | | Fasting glucose | 126 to 280 mg/dL at screen | ___ mg/dL | | eGFR | ≥30 mL/min/1.73m² (most) | ___ mL/min | | BMI | ≥25 to 30 kg/m² | ___ kg/m² | | CV history | Established CVD or high-risk | Yes / No | | Background therapy | Stable ≥8 to 12 weeks | Confirm dates | | Insulin naive vs. Insulin-experienced | Protocol-specific | Yes / No | | Prohibited meds | GLP-1 RA, SGLT2i (varies) | List current meds |

Confirm your values with a lab draw dated within 90 days. Trials that require a "washout" of current agents for 4 to 8 weeks before randomization will show this explicitly in the eligibility section of their ClinicalTrials.gov listing.

What Happens After You Enroll

Randomization assigns you to active drug or placebo (or active comparator) by a blinded algorithm. Phase 3 trials commonly use a 2:1 active-to-placebo ratio, meaning roughly two in three participants receive the investigational agent. The investigator, pharmacist, and participant are all blinded in double-blind designs.

Unblinding and Rescue Criteria

Every protocol defines a rescue criterion: typically two consecutive HbA1c measurements above 10.5%, or a single measurement above 11.0% with symptoms. Rescue allows open-label intensification of background therapy without unblinding or exiting the trial. The FDA's guidance on antidiabetic drug development specifies that protocols must include rescue provisions to protect participants from prolonged severe hyperglycemia. [10]

Early Withdrawal and Your Rights

You may withdraw at any time without penalty. The trial site is required to offer a follow-up safety visit 30 days after your last dose. Any serious adverse event that occurred while on study drug must be reported to the sponsor regardless of withdrawal status, as required under 21 CFR Part 312. Your primary care physician receives a summary of your participation including all study labs, which often includes a full metabolic and lipid panel at no cost to you.

Questions to Ask the Trial Coordinator Before Signing Consent

Bring this list to your first call:

1. What is the probability I receive active drug vs. Placebo?
2. Is there an open-label extension after the blinded period?
3. What rescue therapy is available if my HbA1c rises above threshold?
4. Are all study visits covered, including labs, ECGs, and imaging?
5. Is travel reimbursement available, and at what rate per visit?
6. Who do I contact at 2 a.m. If I have a hypoglycemic episode?
7. Will my primary care physician receive my study lab results?
8. If the drug is approved, will I have access to it after the trial ends?

The International Council for Harmonisation (ICH) E6(R2) Good Clinical Practice guidelines require that all of these questions be addressed in the informed consent document. [13] If the coordinator cannot answer all eight before you sign, ask for a copy of the consent form to review with your own physician first.